Name: Latest research reports of Sun Pharmaceutical Industries Ltd. authored by ICICI Securities Limited and published by - Trendlyne research reports.
Item: Sun Pharmaceutical Industries Ltd.
Rating: 4
Author: ICICI Securities Limited

Summary	Date	Stock	Author	LTP	Target	Price at reco (Change since reco%)	Upside(%)	Type	Report	Discuss
	15 Sep 2025	Sun Pharmaceutical	Consensus Share Price Target	1602.00	1930.16	-	20.48	buy	pdf Detailed Estimates
	04 Aug 2023	Sun Pharmaceutical	ICICI Securities Limited Reco Target	1602.00	1255.00	1138.95 (40.66%)	Target met	Accumulate	pdf post cache	Broker Report US generics drives the Q1 show; launched 10 new products ICICI Securities Limited Sun Pharmaceutical’s (Sun) Q1FY24 performance was driven by better sales of generics in the US, while specialty growth took a back seat. US generics’ business ex-Taro rose 10% QoQ. Impact of lower sales of Levulan in Q1 was largely offset by higher sales of gRevlimid (estimated at USD 35-40mn) and helped Sun report an in-line result. pdf Copy Link Share on Share on Share on Share on Alert
	03 Aug 2023	Sun Pharmaceutical	Prabhudas Lilladhar Target	1602.00	1265.00	1141.00 (40.40%)	Target met	Buy	pdf post cache	Broker Report SUN PHARMACEUTICAL I Prabhudas Lilladhar pdf Copy Link Share on Share on Share on Share on Alert
	03 Aug 2023	Sun Pharmaceutical	BOB Capital Markets Ltd. Reco Target	1602.00	1160.00	1141.00 (40.40%)	Target met	Hold	pdf post cache	Broker Report Sun Pharma (HOLD): gRevlimid buoys performance; upside capped cut to HOLD BOB Capital Markets Ltd. Q1 revenue/EBITDA beat consensus by 2%/11%, but reported PAT missed estimates by 6% due to exceptional items pdf Copy Link Share on Share on Share on Share on Alert
	02 Aug 2023	Sun Pharmaceutical	IDBI Capital	1602.00	1230.00	1135.25 (41.11%)	Target met	Buy	pdf post cache	Broker Report Technical pick update 01 - SUN PHARMA IDBI Capital pdf Copy Link Share on Share on Share on Share on Alert
	07 Jul 2023	Sun Pharmaceutical	IDBI Capital	1602.00	1230.00	1035.70 (54.68%)	Target met	Buy	pdf post cache	Broker Report TECHNICAL PICK: SUN PHARMA IDBI Capital pdf Copy Link Share on Share on Share on Share on Alert
	14 Jun 2023	Sun Pharmaceutical	Motilal Oswal	1602.00	1160.00	986.70 (62.36%)	Target met	Buy	pdf post cache	Broker Report Promising growth outlook for Specialty brands Motilal Oswal pdf Copy Link Share on Share on Share on Share on Alert
	31 May 2023	Sun Pharmaceutical	Geojit BNP Paribas Reco Target	1602.00	1101.00	975.35 (64.25%)	Target met	Buy	pdf post cache	Broker Report SUN PHARMA Geojit BNP Paribas pdf Copy Link Share on Share on Share on Share on Alert
	30 May 2023	Sun Pharmaceutical	BOB Capital Markets Ltd. Reco Target	1602.00	1130.00	959.60 (66.94%)	Target met	Buy	pdf post cache	Broker Report Sun Pharma (BUY): gRevlimid yields margin surprise; raise to BUY post correction BOB Capital Markets Ltd. Q4 revenue in line but adj. PAT 9% above consensus at Rs 21.8bn (+46% YoY) on account of strong margins pdf Copy Link Share on Share on Share on Share on Alert
	30 May 2023	Sun Pharmaceutical	SMC online	1602.00		959.60 (66.94%)			pdf post cache	Broker Report Sun Pharmaceutical Industries SMC online pdf Copy Link Share on Share on Share on Share on Alert
	29 May 2023	Sun Pharmaceutical	Sharekhan Target	1602.00	1123.00	975.35 (64.25%)	Target met	Buy	pdf post cache	Broker Report Sun Pharma Sharekhan pdf Copy Link Share on Share on Share on Share on Alert
more loading

Near 52W Low of ₹1553.05

Sun Pharmaceutical Industries Ltd. share price target

Sun Pharmaceutical Industries Ltd. has an average share price target of 2050.25. The consensus estimate represents an upside of 27.98% from the last price of 1602. View 14 reports from 8 analysts offering long-term price targets for Sun Pharmaceutical Industries Ltd..

US generics drives the Q1 show; launched 10 new products

SUN PHARMACEUTICAL I

Sun Pharma (HOLD): gRevlimid buoys performance; upside capped cut to HOLD

Technical pick update 01 - SUN PHARMA

TECHNICAL PICK: SUN PHARMA

Promising growth outlook for Specialty brands

SUN PHARMA

Sun Pharma (BUY): gRevlimid yields margin surprise; raise to BUY post correction

Sun Pharmaceutical Industries

Sun Pharma

Advisor Screeners